Skip to main content
. 2015 Oct 21;7(3):3623–3634. doi: 10.18632/oncotarget.6211

Figure 3. Overall survival and disease-free survival (DFS) of AML patients with hypocellular characteristics induced with XA or HAG.

Figure 3

Figure 3

The median survival time for patients induced with XA and HAG was 7 and 16 months, respectively A., P = 0.02. The median disease-free survival (DFS) was 6.5 and 16 months, respectively B., P = 0.2